Neurocrine Accounts Payable from 2010 to 2025

NBIX Stock  USD 116.18  0.58  0.50%   
Neurocrine Biosciences Accounts Payable yearly trend continues to be fairly stable with very little volatility. Accounts Payable is likely to outpace its year average in 2025. Accounts Payable is the amount Neurocrine Biosciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Neurocrine Biosciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
1996-03-31
Previous Quarter
95.7 M
Current Value
110 M
Quarterly Volatility
74.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 7.4 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Neurocrine Biosciences over the last few years. An accounting item on the balance sheet that represents Neurocrine Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Neurocrine Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Neurocrine Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Neurocrine Accounts Payable Regression Statistics

Arithmetic Mean35,567,375
Geometric Mean7,774,970
Coefficient Of Variation121.88
Mean Deviation36,230,297
Median13,801,000
Standard Deviation43,348,235
Sample Variance1879.1T
Range115.4M
R-Value0.91
Mean Square Error364.3T
R-Squared0.82
Slope8,240,059
Total Sum of Squares28186T

Neurocrine Accounts Payable History

2025115.5 M
2024110 M
2023108.9 M
202267.3 M
202151.5 M
202039.4 M
201946.2 M

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Accounts Payable, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable110 M115.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.